Jennifer Friel Goldstein serves as Independent Director of the Company. She has 20 years of investing, banking, business development, portfolio management, and strategy experience, as well as a biotechnology background. Since November 2012, Ms. Goldstein held several positions with Silicon Valley Bank (“SVB”) and currently serves as the Head of Business Development, Technology and Healthcare, where she is responsible for business development, venture capital relationship management, and corporate relationship management across all sectors for the bank. From July 2006 to September 2012, Ms. Goldstein served on Pfizer Inc.’s Venture Capital team, during which time she helped lead or co-lead fund-of-fund investment decisions and manage Pfizer's private equity portfolio. Ms. Goldstein has also served as a consultant at Bain & Company in London, where she focused on private equity transactions across Europe. Additional experience at companies such as Chiron, Genelabs, and Genencor further developed Ms. Goldstein’s diverse operational and research skills. Ms. Goldstein also serves on the board of the Leukemia & Lymphoma Society in Silicon Valley. Ms. Goldstein graduated magna cum laude with a Bachelor of Science in Engineering degree in Bioengineering and a Master of Biotechnology degree from the University of Pennsylvania. Ms. Goldstein was also named a Joseph Wharton Fellow while completing her Master of Business Administration degree at the Wharton School.
Jennifer Goldstein is 40, she's been the Independent Director of Alexandria Real Estate Equities since 2020. There are 30 older and 1 younger executives at Alexandria Real Estate Equities. The oldest executive at Alexandria Real Estate Equities Inc. is John Atkins, 76, who is the Independent Director.
Jennifer's mailing address filed with the SEC is C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA, CA, 91101.
Over the last 23 years, insiders at Alexandria Real Estate Equities have traded over $321,052,616 worth of Alexandria Real Estate Equities stock and bought 2,600 units worth $206,214 . The most active insiders traders include Joel S Marcus, Dean A Shigenaga e Stephen Richardson. On average, Alexandria Real Estate Equities executives and independent directors trade stock every 13 days with the average trade being worth of $838,031. The most recent stock trade was executed by Orraparn C. Lee on 13 March 2024, trading 3,000 units of ARE stock currently worth $380,010.
alexandria real estate equities, inc. (nyse:are) is the largest and leading office reit uniquely focused on collaborative science and technology campuses in urban innovation clusters. alexandria pioneered this niche in 1994 and has since established a dominant market presence in aaa locations, including greater boston, san francisco, new york city, san diego, seattle, maryland, and research triangle park. alexandria is known for its high-quality and diverse client tenant base. alexandria has a longstanding and proven track record of developing class a assets clustered in urban science and technology campuses that provide its innovative client tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success.
Alexandria Real Estate Equities executives and other stock owners filed with the SEC include: